Therapy, Toxics and drugs

• therapeutic drugs
  29 January 2006

  List of drugs at www.humpath.com
  An adverse drug reaction is defined as a toxic or undesired response to a drug used at therapeutic doses to prevent, diagnose, or treat disease.
  It is estimated that approximately 2 million hospitalized patients suffered from serious adverse drug reactions in 1994, resulting in 106,000 deaths. These estimates are conservative because they do not include errors in drug dosage or administration or patient noncompliance.
  Predictable reactions are based on the (...)

• taxanes
  5 January 2006

  Definition : Taxanes are a class of diterpenes.
  Taxanes were originally identified from plants of the genus Taxus (yews), and feature a taxadiene core.
  Molecules as paclitaxel (Taxol) and docetaxel (Taxotere) are widely used as chemotherapy agents. cabazitaxel was FDA approved to treat hormone-refractory prostate cancer.
  Taxanes are important drugs in the treatment of ovarian and other cancers, but their efficacy is limited by intrinsic and acquired drug resistance.
  Resistance (...)

• methotrexate
  28 November 2005

  MTX

• halothane
  14 October 2005

  Pathology
  mild form of hepatotoxicity (20%)
  halothane hepatitis halothane-associated massive hepatic necrosis (halothane fulminant hepatitis)

• bisphosphonate
  6 September 2005

  References
  Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med. 2002 Sep;2(6):571-7. PMID: #12243249#

• drug-induced anomalies
  15 June 2005

  Types
  drug-induced toxicity
  drug-induced metabolic anomalies
  drug-induced malformations
  drug-induced lesions
  drug-induced lesional syndromes
  drug-induced diseases
  drug-induced tumors
  See also
  drugs

• minocycline
  15 June 2005

  minocycline-induced anomalies
  Pathology
  drug-induced hepatitis (minocycline-induced hepatitis)
  drug-induced acute hepatitis
  minocycline-induced pneumonitis
  drug-induced immune thrombocytopenic purpura (DITP) (#12848117#)
  autoimmune features
  minocycline-induced lupus
  serum anti-nuclear antibodies
  elevated immunoglobulin G
  perinuclear antineutrophilic cytoplasmic antibody (pANCA )
  lupus-like syndromes
  serum sickness
  infectious mononucleosis-like syndrome
  vasculitis (...)

• immune-mediated adverse drug effects
  12 June 2005

  IMADEs

• HIV integrase inhibitors
  12 June 2005

  References
  Ciuffi A, Bushman FD. Retroviral DNA integration: HIV and the role of LEDGF/p75. Trends Genet. 2006 Jul;22(7):388-95. PMID: #16730094#
  Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236-48. PMID: #15729361#

• platinum
  12 June 2005

  The accidental discovery of the anticancer properties of cisplatin and its clinical introduction in the 1970s represent a major landmark in the history of successful anticancer drugs.
  Although carboplatin—a second-generation analogue that is safer but shows a similar spectrum of activity to cisplatin—was introduced in the 1980s, the pace of further improvements slowed for many years.
  However, in the past several years interest in platinum drugs has increased.
  Key developments include the (...)

0 | ... | 80 | 90 | 100 | 110 | 120 | 130 | 140 | 150 | 160 | 170